Updated from ASH and ACCP – DOAC Dosing for VTE: What You Need to Know
Dr. Chokri Ben Lamine shared on X:
Based on ASH 2024 and ACCP 2021 Guidelines
”VTE Treatment (Therapeutic Anticoagulation)”
-Apixaban:
▸ 10 mg BID × 7 days → 5 mg BID
▸ Optional: 2.5 mg BID after 6 months (extended use)Rivaroxaban:
▸ 15 mg BID × 21 days → 20 mg OD
▸ Optional: 10 mg OD after 6 monthsEdoxaban:
▸ Parenteral anticoagulation × 5–10 days → 60 mg OD
▸ Reduce to 30 mg if CrCl 15–50 or weight ≤60 kgDabigatran:
▸ Parenteral anticoagulation × 5–10 days → 150 mg BIDVTE Prophylaxis (Post-op, High Risk)
-Apixaban: 2.5 mg BID-Rivaroxaban: 10 mg OD
-Dabigatran: 110 mg Day 1 → 220 mg OD
-Edoxaban: Not typically used for primary prophylaxis
Key Precautions
-Age >75-CrCl <30 mL/min
-Low body weight
-Active cancer → Consider LMWH
Always assess bleeding & renal function risk.”
You can Find more Posts on Hemostasis Today.
-
Aug 5, 2025, 17:44Brain Haemorrhage: A Critical Awareness Guide by Dr. Dilip S. Kiyawat
-
Aug 5, 2025, 07:09EHJ Issue 46-29 Explores Cardio-Oncology and Ischaemic Syndrome Management – Now Online
-
Aug 5, 2025, 04:46When the Same Risk Can Be a Benefit – The Balance Between Bleeding and Thrombosis
-
Aug 5, 2025, 04:02Julia Rauscher and Cathy Verbraeken Lead EHC Workshop on Best Practices
-
Aug 5, 2025, 02:28Personalized Perioperative Management in Hemophilia: Key Insights from Heghine Khachatryan
-
Aug 5, 2025, 19:27Ming Y Lim Presents the Clot Cases Conference: Model of Advanced Multidisciplinary Thrombosis Care
-
Aug 5, 2025, 18:49Francois Delvoye and Jean‐Philippe Désilles: Neutrophil Activation Affects Acute Ischemic Stroke Clinical Outcomes?
-
Aug 4, 2025, 17:29MADD: First Causal Gene for Quantitative Von Willebrand Disease Discovered
-
Aug 4, 2025, 16:13Nicolas Gendron on TITAN’s Recent Study: Insights on Managing Pregnancy in Antithrombin Deficiency
-
Aug 4, 2025, 01:59Michael Makris Posts Haemophilia Journal Article Reassessing UK Blood Inquiry
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 5, 2025, 17:59Heghine Khachatryan: Honored to Be Part of The WFH Regional Workshop 2025
-
Aug 4, 2025, 05:20NBCA: Alexis’s DVT Diagnosis Came Without Warning - Learn How She Caught It Early
-
Aug 4, 2025, 00:50NBCA: After Losing Her Daughter to a Blood Clot, Charita Fights to Save Others
-
Aug 3, 2025, 18:10Andrew Agwunobi Congrats Dr. Oladipo Cole and The Whole Team at the Connecticut Bleeding Disorder Center
-
Aug 3, 2025, 12:03Elias Bouchi Presents Werfen EEMEA Talks on Hemostasis: Clot Stories Season 3